On July 2, the U.S. Food and Drug Administration granted traditional approval to Eli Lilly's donanemab, marketed as Kisunla (kih-SUHN-lah), for treating early symptomatic Alzheimer's disease. This approval covers individuals with mild cognitive impairment and mild dementia stages of Alzheimer's with confirmed amyloid plaques. Kisunla is the third drug approved by the FDA that alters the disease's underlying progression.

In a significant legislative move, Illinois became the first state to mandate insurance coverage for Alzheimer's treatments, improving access to these progressive disease-slowing drugs. With nearly 7 million Americans affected by Alzheimer's, it remains a leading cause of death in the country. Over 11 million family members and friends also provide care to those with Alzheimer's and other dementias, with Illinois alone accounting for more than 266,500 patients and 314,000 caregivers.

For more information, visit alz.org/facts. Support and information from the Alzheimer's Association are available 24/7 for individuals with Alzheimer's and their caregivers at 800.272.3900.